Treating bone cancer pain continues to be a clinical challenge and underlying mechanisms of bone cancer pain remain elusive. Here, we report that EphB1 receptor forward signaling in the spinal cord is critical to the development of bone cancer pain and morphine tolerance in treating bone cancer pain. Tibia bone cavity tumor cell implantation (TCI) produces bone cancer-related thermal hyperalgesia, mechanical allodynia, spontaneous and movement-evoked pain behaviors, and bone destruction. Production and persistence of these pain behaviors are well correlated with TCI-induced upregulation of EphB1 receptor and its ligand ephrinB2 in the dorsal horn and primary sensory neurons. Spinal administration of an EphB1 receptor blocking reagent EphB2-Fc prevents and reverses bone cancer pain behaviors and the associated induction of c-Fos and activation of astrocytes and microglial cells, NR1 and NR2B receptors, Src within the N-methyl-D-aspartate receptor complex, and the subsequent Ca 2þ -dependent signals. The exogenous ligand ephrinB2-Fc upregulates level of phosphorylation of NR1 and NR2B receptors depending on the activation of EphB1 receptor. Spinal administration of EphB2-Fc and ephrinB2-Fc induces downregulation of EphB1 and ephrinB2, respectively, accompanied with increased activity of matrix metalloproteinase (MMP)-2/9. Blocking MMP-2 or MMP-9 reverses EphB1-Fc treatment-induced downregulation of EphB1 receptor. In addition, spinal blocking or targeted mutation of EphB1 receptor reverses morphine tolerance in treating bone cancer pain in rats and defensive pain in mice. These findings show a critical mechanism underlying the pathogenesis of bone cancer pain and suggest a potential target for treating bone cancer pain and improving analgesic effect of morphine clinically. Cancer Res; 71(13); 4392-402. Ó2011 AACR.
Introduction
Bone cancer pain is one of the most common symptoms presented by patients with primary bone sarcomas and predominantly occurs as distant metastases of non-bone primary tumors, notably those in breast, prostate, and lung (1, 2) . Tumor cells act to cause pain in many ways. Production of prostaglandin and other molecules by tumors, tumorassociated macrophages, and other host cells stimulate osteoclast-mediated bone resorption. Nociceptors in bone are stimulated via activation of transient receptors potential vanilloid type-1, endothelin A, and TrkA receptor. Activation is directed by acid microenvironment, endothelin-1, and nerve growth factor, respectively (2) . Mechanisms of bone cancer pain are complex and may involve a combination of inflammatory and neuropathic pain (2, 3) with unique characteristics. For instance, bone cancer pain markedly increases expression of glial fibrillary acidic protein (GFAP; ref. 4 ), but not substance P and calcitonin gene-regulated peptide (CGRP) in the dorsal horn (DH) of the spinal cord or galanin and neuropeptides Y in dorsal root ganglion (DRG) neurons (2) . Despite decades of thorough study, the specific cellular and molecular mechanisms underlying bone cancer pain remain elusive and the clinical approaches for treating bone cancer pain are limited.
Eph receptors, named for its expression in an erythropoietinproducing human hepatocellular carcinoma cell line, consist of the largest family of receptor tyrosine kinases, which play vital roles in transmitting external signals to the interior of many types of cells. EphB receptors and their ligands ephrinBs are critical cues in regulating cell shape, adhesion/repulsion, migration, and positioning during developmental processes (5) (6) (7) . Alteration of mechanisms controlling adhesion and motility has a central role in promoting tumor invasion and angiogenesis (8) (9) (10) . Altered expression of ephrins and/or Eph receptors has been implicated in tumor progression in a number of human malignancies (11) (12) (13) . Recently, we have found that ephrinB-EphB receptor signaling is involved in pain after nerve injury or opiate withdrawal (14) (15) (16) . We hypothesized that the ephrinB-EphB receptor signaling might play an important yet unknown role in development of bone cancer pain. EphrinB-EphB interaction is well known to lead bidirectional signals, the forward and the reverse signaling (17) . There is no clear evidence if either the forward or the reverse signaling or both is necessary for production and/or persistence of any pain status. Here, we show that the forward but not the reverse signaling of EphB1 receptor in the spinal cord is critical to development of bone cancer pain. Spinal inhibition of EphB1 receptor can relieve bone cancer pain and rescue analgesic effect of morphine in treating bone cancer pain.
Materials and Methods

Animals, anesthesia, drugs, and administration
All animals were used in accordance with the regulations of the ethics committee of the International Association for the Study of Pain and all protocols approved by the Institutional Animal Care and Use Committees. Adult, male, and SpragueDawley rats; adult, male, and female CD-1 mice (Charles River Laboratories); and the EphB1 À/À and EphB1 þ/þ mice (Hen- ) and MMP-9 (FN439) were used to determine possible roles of MMP-2/9 in modulation of EphB1. Each of the drugs used was dissolved in PBS or dimethyl sulfoxide (DMSO) and then injected intrathecally (i.t., 10 mL for mice and 20 mL for rats) by means of lumbar puncture at the intervertebral space of L 4-5 and L 5-6 for multiple injections. These drugs and their final concentrations were: EphB2-Fc (2 or 5 mg), ephrinB2-Fc (2 mg), FN439 (100 mg), MMP2i (10 mg), DMSO (1%; Sigma-Aldrich), and immunoglobulin (Ig) G-Fc (2 or 5 mg, Jackson Laboratories).
Model of bone cancer pain
Tumor cells were extracted from ascitic fluid of rats that received Walker-256 rat mammary gland carcinoma cells. TCI was mimicked by injecting the cells (1 Â 10 5 cells/mL, 5 mL) into the intramedullary space of the right tibia to induce bone cancer in rats (18) .
Assessment of bone cancer-related pain behaviors
Thermal hyperalgesia was determined by the significant shortened latency of foot withdrawal in response to heat stimulation. Mechanical allodynia was indicated by a significant decrease in the threshold of paw withdrawal to mechanical indentation of the plantar surface of each hindpaw. The protocols were similar to those described previously (19, 20) .
Western blotting
Protein precipitation procedures in conjunction with Western blots were employed to identify temporal expression of EphB1, ephrinB2 protein, and their phosphorylation. Protocols were similar to those described previously (14, 21) . EphB1 and ephrinB2 were immunoprecipitated from 2 mg total protein/mL tissue lysate by using an anti-EphB1 antibody [2 mg; Santa Cruz Technology (SCT)] complex with protine Gagarose (Invitrogen) and wheat germ agglutinin linked to agarose (Sigma), respectively. EphrinB2 and its phosphorylation were detected by anti-ephrinB2 (C20, SCT) and antiphosphotyrosine antibody PY99 (SCT), respectively (22) . EphB1 and its phosphorylation were detected by anti-EphB1 antibody (Q20, SCT) and phosphotyrosine antibody 4G10 (Upstate Biotechnology), respectively (23) . NR2A immunoprecipitation was done by anti-NR2A antibody followed by adsorption to protein G-agarose. Whole-cell protein extracts lysates were used to identify temporal expression of the phosphorylated protein levels of NR1(pNR1), NR2B(pNR2B), Src(pSrc), extracellular signal regulated kinase (ERK; pERK), CaMKII(pCaM-KII), cAMP responsive element binding protein (CREB; pCREB), and glyceraldehyde 3-phosphate dehydrogenase (GAPDH). The primary antibodies were used including pNR1(Ser897), 1:800 (Millipore); pNR2B(Tyr1472), 1:300 (Chemicon); pSrc(Tyr418), 1:800 (Abcam); pERK1/2(Thr202/ Tyr204), 1:500; pCaMKII(Thr286), 1:1,000 (Cell Signaling Technology); GAPDH, 1:1,000 (Sigma); and GFAP and pCREB (Ser133)(SCT). The filters were then developed by enhanced chemiluminescence reagents (Perkinelmer) with secondary antibodies (Chemicon). Data were analyzed with a Molecular Imager (Gel DocTM XR, 170-8170) and the associated software Quantity One-4.6.5 (Bio-Rad Laboratories).
Immunohistochemistry
Sections of the spinal cord or DRG tissues were incubated with polyclonal rabbit antibodies of anti-EphB1 (1:20) and anti-ephrinB2 (1:20; SCT) and mouse monoclonal antineuronal nuclear protein (NeuN; 1:100; Alexa Fluor-488 conjugated, MAB377X; Chemicon). Rabbit IgG (1:200; Vector Laboratories) was used as an isotype control. Morphologic details were examined with a confocal microscope (Leica TCS SP2, Germany). The protocols were similar to those described previously (14, 21) .
Morphine tolerance tests
Each of CD-1, EphB1
, or EphB1 À/À mice were placed on a 55 C hot plate apparatus and the latency to lick a paw was measured following s.c. morphine injection. Protocol for testing acute tolerance (Mor100-10): the latency to lick a paw was measured at 0.5, 1, 1.5, and 2 hours following the second dose (10 mg/kg, i.p.) administrated 24 hours after the first dose of morphine (100 mg/kg). Protocol for testing chronic tolerance (Mor10): morphine (10 mg/kg) was injected daily for 7 days, and the analgesic effect was measured 30 minutes after each injection. To examine the role of EphB receptor in morphine tolerance, EphB2-Fc (2 mg, i.t.), or its Fc control was administrated 30 minutes prior to the morphine at 100 mg/kg in acute tolerance or each of the morphine injection at 10 mg/kg in the chronic tolerance in CD-1 mice.
Statistical analyses
SPSS Rel 15 was used to conduct all the statistical analyses. Alteration of expression of the proteins detected and the behavioral responses to thermal and mechanical stimuli over time among groups were tested with 1-way and 2-way ANOVA with repeated measures followed by Bonferroni post hoc tests, respectively. All data are presented as meansAESEM. Statistical results are considered significant if P < 0.05.
Results
Activity and distribution of EphB1 and ephrinB2 in the spinal cord following TCI Level of protein expression and phosphorylation of EphB1 receptor and its ligand ephrinB2 in the spinal cord was increased significantly in a time-dependent manner after TCI, whereas they were at low levels in naive rats ( Fig. 1A and B). Phosphorylation of EphB1 was slightly decreased on the postoperative 21 days, but not altered during postoperative 3 to 14 days because ratio of EphB1 and pEphB1 was remained the same. The increased EphB1 and ephrinB2 immunoreactivity was distributed predominately in the superficial DH ipsilateral to TCI (Fig. 1C ). EphB1 immunoreactivity was colocalized primarily with neurons ( Fig. 1D ) and astrocytes, while only a small amount with microglia (Supplementary Blocking EphB1 receptor activation prevents and suppresses behavioral and neurochemical signs of bone cancer pain Rats that received TCI exhibited thermal hyperalgesia and mechanical allodynia (Fig. 2) . They also exhibited spontaneous pain manifested as guarding and movement-evoked pain manifested as guarding, flinching, and reduced limb use ( Supplementary Fig. S2 ). Production and persistence of these pain-related behaviors were greatly delayed and suppressed by an EphB1 receptor inhibitor EphB2-Fc administrated (each 5 mg, i.t., once a day) at postoperative 3, 4, and 5 days ( Supplementary Fig. S2 ), respectively. Normal pain sensation was not altered. In addition, TCI caused induction of c-Fos and activation of astrocytes and microglial cell in the DH ipsilateral to TCI. These alterations were inhibited by repetitive treatments with EphB2-Fc ( Supplementary Fig. S3 ). These results suggest that ephrinB-EphB receptor signaling may play an important role in production and persistence of bone cancer pain. In addition, pathological observations (X-ray and hematoxylin-eosin staining) showed that bone destruction associated with tumor growth seemed to be slightly improved following such transient EphB2-Fc treatment ( Supplementary  Fig. S4 ).
Blocking EphB1 receptor activation suppresses TCI-induced increase of level of pNR1, pNR2B, pSrc, pERK, pCaMKII, and pCREB in the spinal cord N-methyl-D-aspartate receptors (NMDAR) have a welldeveloped role in neural plasticity and various pain states. Src family kinases can enhance NMDAR function (24) (25) (26) and ephrinB2 may activate NR2B receptor via Src during inflammatory hyperalgesia (27) . TCI treatment significantly increased levels of pNR1, pNR2B, pSrc (Tyr418; Fig. 3A) , pERK, pCaMKII, and pCREB (Fig. 3B) . Timing patterns of upregulation of these phosphorylated molecules were well matched with that of bone cancer pain-related behaviors (see Fig. 2 ). Repetitive treatment with EphB2-Fc (each 5 mg, i.t., once a day on postoperative 7, 8, and 9 days, respectively) inhibited the expression of these molecules (Fig. 3) . Expression of pNR2A was neither altered by TCI nor EphB2-Fc treatment (Fig. 3A) . These results suggest that TCI-induced activation of NR1 and NR2B receptors, Src, and the subsequent Ca 2þ -dependent signals may be secondary to activation of the ephrinB-EphB receptor signaling.
EphB2-Fc inhibits TCI-induced increase in expression of EphB1 but not ephrinB2
EphrinB-EphB interaction is well known to lead bidirectional signals, the forward and the reverse signaling (17) . There is no evidence if either the forward or the reverse signaling or both are necessary for production and maintenance of any pain status. Here, we showed that TCI-induced upregulation (D) is indicated by the arrows. TCI was done on day 0 (~). Eight rats were included in each group. *, P < 0.05 and **, P < 0.01 indicate significant differences compared to the group of control (ShamþFc). #, P < 0.05 and ##, P < 0.01 indicate significant differences compared to the corresponding TCI group. (Fig. 4A) or repetitive doses on postoperative 7, 8, and 9 days, respectively (Fig. 4B) . Inhibition occurred within 2 hours and persisted for at least a week. EphB2-Fc treatment did not affect TCI-induced increase of expression of ephrinB2 and PY99 (Fig. 4C) . These results, together with those shown in Figure  3 , indicate that EphB1 downregulation may contribute to inhibition of pNR1, pNR2B, pSrc(Tyr418), pERK1/2, pCaMKII, and pCREB and reduction of bone cancer pain behaviors following EphB2-Fc treatment; whereas continuous activation of ephrinB2 is unable to maintain activation of these signals and the pain status.
EphrinB2-Fc activates NR1 and NR2B and induces thermal hyperalgesia on the condition of EphB1 receptor activation in naive rats
Spinal administration of an exogenous EphB1 receptor activator ephrinB2-Fc (2 mg) increased the level of pEphB1, but not the overall receptor expression of EphB1 (Fig. 5A) , and upregulated levels of pNR1 and pNR2B (Fig. 5B) . It also decreased ephrinB2 expression, but not its phosphorylation PY99, because the ratio ephrinB2/PY99 was maintained at the same level ( Supplementary Fig. S5A ) and resulted in thermal hypersensitivity (Supplementary Fig. S5B ). Repetitive ephrinB2-Fc (2 mg, i.t., once a day for 3 consecutive days) produced similar effects on phosphorylation or expression of these molecules and thermal hypersensitivity (Supplementary Fig. S6 ). We further examined whether ephrinB2-Fcinduced activation of NR1 and NR2B and thermal hypersensitivity would be dependent on activation of the EphB1 receptor. TCI-induced upregulation of EphB1 was inhibited by EphB2-Fc treatment (see Fig. 4 ). In naive rats, EphB2-Fc treatment (5 mg, for 3 consecutive days) greatly inhibited expression of EphB1 and its phosphorylation (Fig. 5C ). Under this condition, ephrinB2-Fc (2 mg) failed to activate or rescue EphB1 (Fig. 5C) , NR1, and NR2B (Fig. 5D ), but continued to downregulate ephrinB2 ( Supplementary  Fig. S7A ). In addition, ephrinB2-Fc treatment caused thermal hypersensitivity in naive rats, but failed to do so when coadministrated with EphB2-Fc (Supplementary Fig. S7B ). These results indicate that activation of EphB1 receptor is required for ephrinB2-Fc to activate NR1 and NR2B and further induce thermal hypersensitivity, suggesting that EphB1 and NR1/2 activation is necessary for the development of thermal hyperalgesia. Downregulation of ephrinB2 is not sufficient or unnecessary for ephrinB2-Fc-induced thermal hypersensitivity. Blocking EphB receptor activation suppresses TCI-induced upregulation of pNR1, pNR2B, pSrc(Tyr418), pERK1/2, pCaMKII, and pCREB in the spinal cord. EphB2-Fc (5 mg, i.t., daily) was administrated at postoperative 7, 8, and 9 days, respectively. Four samples were included in each of pNR1, pNR2B, and pSrc(Tyr418) groups and 3 in the other groups. *, P < 0.05 and **, P < 0.01 indicate significant differences compared to the control (Sham and ShamþFc). #, P < 0.05 and ##, P < 0.01 indicate significant differences compared to the corresponding group of TCIþFc on the specific day indicated.
Inhibition of MMP-2 or MMP-9 activation prevents EphB2-Fc-induced downregulation of EphB1 in naive and TCI rats Spinal administration of EphB2-Fc results in downregulation of EphB1 protein, in addition to inhibition of TCIinduced pain-like behaviors and neurochemical alterations. Since EphB-ephrinB interactions can be broken by MMPs, which cleaves EphB receptors (28-30), we examined possible roles of spinal MMP-9/2 in EphB2-Fc-induced EphB1 downregulation. With EphB2-Fc administration, levels of EphB1 and pEphB1 were further downregulated from already low levels in naive rats (Fig. 6A ) and TCI rats, back to control (Sham) levels from greatly increased levels (Fig. 6B) , respectively. The EphB2-Fc-induced downregulation of EphB1 was completely prevented by blocking MMP-2 with MMP2i (10 mg) or MMP-9 with FN439 (100 mg; Fig. 6A and B ) and the level of EphB1 was brought back to levels originally seen in (i) naive and (ii) TCI (B), respectively. However, without EphB2-Fc treatment, blocking MMP-2 or MMP-9 inhibited TCI-induced upregulation of EphB1 and brought the upregulated EphB1 back to control (Sham) levels (Fig. 6C, left) , while keeping EphB1 at its physiological levels in naive rats (Fig. 6C, right) . Administration of exogenous MMP-2 or MMP-9 caused an increase rather than a decline in the activation (phosphorylation) of EphB1 without altering the expression of EphB1 protein in naive rats (Fig. 6D, left) and did not significantly alter increased levels of EphB1 in TCI rats (Fig. 6D, right) . Gelatin zymography showed that activity of both MMP-2 and MMP-2 was greatly increased following EphB2-Fc or ephrinB2-Fc treatment (Supplementary Fig. S8 ). These results indicate that MMP-2/9 have different roles, with and without EphB2-Fc treatment, in the modulation of EphB1. With EphB2-Fc treatment, they held EphB1 back to the reference levels which are relatively low in naive rats and greatly increased in TCI rats. Without EphB2-Fc treatment, they may upregulate the EphB1 level.
Blocking EphB1 receptor activation rescues analgesic effect of morphine in treating bone cancer pain
Morphine has been used in reducing cancer pain, particularly in advanced and terminal patients, but its tolerance following repeated use has limited its clinical use. Given that EphB1 receptor may be a potential target for treating bone cancer pain, we extended our experiments to examine whether morphine tolerance in treating bone cancer pain would be involved in the activation of ephrinB-EphB signaling. Injection of morphine (10 mg/kg, s.c., twice a day, 12 hours intervals) significantly suppressed thermal hyperalgesia in TCI rats. Such an analgesic effect decreased and then disappeared (tolerance) 6 to 7 days after repeated use of morphine (Fig. 7A) . Coadministration of EphB2-Fc at lower doses (each 2 mg accompanied with morphine), which alone was not enough to reduce the hyperalgesia, successfully rescued the analgesic effect of morphine (prevented morphine tolerance) in treating bone cancer hyperalgesia (Fig. 7A) . Meanwhile, increased level of phosphorylation and expression of EphB1 following TCI Figure 4 . Spinal administration of EphB2-Fc inhibits TCI-induced upregulation of expression of EphB1, but not ephrinB2. A, a single dose of EphB2-Fc or its Fc control (each 5 mg) was injected on the 7th day after TCI. B and C, repetitive EphB2-Fc (EphB2-FcÂ3, each 5 mg, once a day) was injected on postoperative 7, 8, and 9 days, respectively. Tissues were collected 2 hours after the last treatment with EphB2-Fc or Fc. **, P < 0.01 indicates significant differences compared to the corresponding group of ShamþFc. #, P < 0.05 and ##, P < 0.01 indicate significant differences compared to the corresponding group of TCIþFc. and morphine treatment were inhibited by repetitive EphB2-Fc treatment (Fig. 7B) .
We further investigated the role of EphB1 receptor in morphine tolerance by using standard protocols for testing acute and chronic morphine tolerance in naive and EphB1 receptor knock out (EphB1 À/À ) mice. Both acute (Fig. 7C ) and chronic ( Fig. 7D ) morphine tolerance were reduced by coadministration of EphB2-Fc (each 2 mg, i.t.) with morphine or by targeted mutation of EphB1. Meanwhile, acute (Supplementary Fig. S9A and B) and chronic ( Supplementary Fig. S9C ) morphine treatment significantly increased the expression of EphB1 and its phosphorylation, and this effect was inhibited by EphB2-Fc ( Supplementary Fig. S9B and C) . These results indicate that the EphB1 receptor is involved in development of morphine tolerance.
Discussion
Our study reveals a critical role for the ephrinB-EphB receptor signaling in bone cancer pain and morphine tolerance in treating bone cancer pain. TCI greatly activates spinal ephrinB2-EphB1 receptor signaling, which then induces activation of NR1 and NR2B receptors and the downstream pathways, resulting in bone cancer pain. EphB1 is required for the production and persistence of bone cancer pain and the functional link among the ephrinB-EphB receptor signaling, NR1 and NR2B receptors, and downstream responses. Cleavage of EphB1 receptor may be mediated by MMP-2 and MMP-9. These findings provide a novel mechanism underlying the pathogenesis of bone cancer pain. EphB1 receptor is also required for the development of morphine tolerance. Thus, EphB1 receptor may be a potential target for treating bone cancer pain and reducing opioid tolerance in treating bone cancer pain clinically.
EphB receptors and their ligands, ephrinBs, are critical cues in regulating cell shape, adhesion/repulsion, migration, and positioning during developmental processes (5-7, 31). Alteration of mechanisms controlling adhesion and motility has a central role in promoting tumor invasion and angiogenesis (8) (9) (10) . Here, we show that TCI-induced activation of EphB1 receptor and its ligand ephrinB2 are well correlated with the timing patterns of TCI-induced bone cancer pain behaviors. The increased EphB1 receptor and ephrinB2 are predominantly localized with neurons and some astrocytes in the DH, an essential area for the generation and processing of pain signals. EphrinB2 in the peripheral nociceptors may be transported and redistributed along the CGRP fibers, to the presynaptic membranes of their central terminals, where it triggers a series of postsynaptic effects. EphB receptors regulate synaptic plasticity by interaction with NMDARs (32) (33) (34) . NMDARs have a well-developed role in neural plasticity and various pain states. Within the NMDAR complex, the nonreceptor tyrosine kinase, Src, provides dynamic gain control of NMDAR function via balancing its activity with striatal enriched tyrosine (24) (25) (26) (27) 35) . We also show that blocking EphB1 receptor activation largely diminished TCI-induced phosphorylation of NR1 and NR2B receptors, Src(Tyr418), and subsequent activation of various Ca 2þ -dependent signaling enzymes, CREB, induction of c-Fos, and bone cancerrelated pain behaviors. Therefore, we hypothesize that peripheral nerve damage due to cancer cell invasion leads to upregulation of the presynaptic ephrinB2 ligand and postsynaptic EphB1 receptor molecules in primary neurons and the DH. Such an increased expression of ephrinB-EphB signaling then leads to postsynaptic EphB1 receptor forward signaling clustering and reciprocal phosphorylation on multiple tyrosine residues (32, 36) . Thus, downstream signaling proteins containing SH2 domains, including Src family kinases (36, 37) , which are physically associated with EphB receptors and NMDARs, and phosphorylate NMDARs on tyrosines (38) may be recruited. This results in the subsequent activation of Ca 2þ -dependent signaling pathways and behavioral manifestations.
We noted the fact that ephrinB2-Fc treatment and TCIinduced thermal hyperalgesia may involve EphB1 receptor, probably via 2 different mechanisms. EphrinB2-Fc treatment may induce true EphB1 receptor activation, because it does not affect overall receptor expression, but increases the level of phosphorylation of EphB1. EphrinB2-Fc treatment also downregulates the expression of both ephrinB2 and PY99. On the contrary, TCI induces an upregulation of both EphB1 and pEphB1, and ephrinB2 and PY99.
EphrinB-EphB interaction is well known to lead bidirectional signals which are propagated into the ephrinB-expressing cells (reverse signaling) and the EphB-expressing cells (forward signaling). It is unknown if either of the forward or reverse signaling or both are important in pain processing. Our findings in this bone cancer model may support that and MMP-9 on EphB1 without EphB2-Fc treatment in naive (left) and TCI (right) rats. Four samples were included in each group. Tissues were taken 4 hours after the last treatment. *, P < 0.05 and **, P < 0.01 indicate significant differences compared to the corresponding control group (Naive or Sham). #, P < 0.05 and ##, P < 0.01 indicate significant differences compared to the corresponding control group [PBS in (A) and TCI in (B)].
EphB1 receptor forward signaling is critical to the development and maintenance of pain and activation of NR1 and NR2B receptors and subsequent Ca 2þ -dependent signals. When EphB1 is inhibited, pain behaviors and NMDARs activation are inhibited even though the ephrinB2 continues to be active. When EphB1 receptor is activated, NMDARs are activated and pain is induced even though ephrinB2 is downregulated. A recent study, by deleting ephrinB2 in Nav1.8 þ nociceptive sensory neurons, indicates that presynaptic ephrinB2 expression may play a role in regulating inflammatory pain and some types of neuropathic pain through the regulation of synaptic plasticity in the DH (39) .
Another interesting phenomenon is that EphB2-Fc treatment results in downregulation of EphB1 protein accompanied with increased activity of MMP-2 and MMP-9 in the spinal cord. Such EphB1 downregulation can be prevented or rescued by blocking MMP-2 or MMP-9. We hypothesize that during EphB2-Fc treatment, EphB2-Fc combines with endogenous ephrinB2 and thus EphB1 is substituted and cleaved EphB1. In summary, MMP-2/9 may mediate EphB1 cleavage during EphB-Fc treatment and thus enhance the inhibitory effect of EphB2-Fc on EphB1 signaling; whereas MMP-2/9 alone may activate rather than cleave EphB1. Interactions between EphB1 and MMPs need to be further examined and they are beyond the scope of this article. Cancer pain posses a major challenge clinically. Opioid drugs, with or without coanalgesics/adjuvant analgesics, are used to treat moderate to severe pain. However, the effective use of morphine as a treatment on such pain is limited by morphine tolerance and concerns related to addiction and opioid administration-associated severe, sometimes debilitating side effects (40) (41) (42) (43) . This study shows that pharmacological blockade or genetic deletion of EphB1 receptor can prevent morphine tolerance in treating bone cancer pain and defensive pain, respectively. In addition, we have recently found that inhibition of EphB1 receptor can prevent or largely diminish morphine physical dependence (14) . Thus, blocking EphB1 receptor may be a potential pharmaceutical therapy that cannot only relieve bone cancer pain, but also facilitate the clinical utility of opioid drugs in treating bone cancer pain.
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